Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|February 18, 2022
Daily Medication Pearl: Vortioxetine (Trintellix)
Author(s)Saro Arakelians, PharmD
Vortioxetine (Trintellix) treats major depressive disorder in adults.
Advertisement
Medication Pearl of the Day: Vortioxetine (Trintellix)
Indication: Trintellix is indicated for the treatment of major depressive disorder in adults.
Insight:
- Dosing: The recommended starting dose is 10 mg administered orally once daily without regard to meals
- Dosage forms: Tablets 5 mg, 10 mg, and 20 mg.
- Adverse events: Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) were nausea, constipation, and vomiting.
- Mechanism of action: The mechanism of the antidepressant effect of vortioxetine is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin.
- Manufacturer: Takeda Pharma
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
5